Assessing Centene: Insights From 6 Financial Analysts
Portfolio Pulse from Benzinga Insights
Six financial analysts have recently updated their ratings on Centene (NYSE:CNC), with a mix of bullish, somewhat bullish, and indifferent perspectives. The average 12-month price target for CNC is now $88.00, up from $78.60, indicating an 11.96% increase. Analysts from Barclays, Wells Fargo, Truist Securities, UBS, and Cantor Fitzgerald have adjusted their ratings and price targets, reflecting optimism about Centene's market performance. Centene, a managed-care organization, has shown strong financial indicators such as revenue growth, net margin, ROE, and ROA, outperforming industry averages. However, its debt-to-equity ratio is higher than the industry average, suggesting financial risk.
March 06, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Centene's stock has received updated ratings and price targets from analysts, indicating a positive outlook with an average price target increase to $88.00. The company's strong financial performance and growth in the healthcare sector are highlighted, though concerns about its high debt-to-equity ratio persist.
The positive revisions in analyst ratings and price targets for Centene reflect a bullish sentiment towards the company's stock in the short term. The increase in the average price target, coupled with Centene's strong financial performance indicators such as revenue growth, net margin, ROE, and ROA, supports a positive outlook. However, the high debt-to-equity ratio introduces a note of caution, suggesting that while the stock is likely to perform well, investors should be mindful of the associated financial risk.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100